NewSquare Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

NewSquare Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5	Closed	-$1.16K	–	767
2023 Q2	$1.16K	Hold	5	–	–	﹤0.01%	592
2023 Q1	$1.21K	Hold	5	–	–	﹤0.01%	630
2022 Q4	$1.45K	Buy	+5	New	+$489	﹤0.01%	530

Other funds holding MDGL

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

NewSquare Capital's MDGL Position: Q3 2023 in Review

NewSquare Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2023, closing a stake of 5 shares — an estimated $1.16K sold.

NewSquare Capital first reported a position in MDGL in Q4 2022 and held it in 3 quarters. The position peaked at $1.45K in Q4 2022. 205 funds tracked by Wall St. Rank hold MDGL as of Q3 2023.

NewSquare Capital reported no remaining Madrigal Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
NewSquare Capital sold 5 Madrigal Pharmaceuticals shares in Q3 2023, an estimated $1.16K.
NewSquare Capital first reported a position in Madrigal Pharmaceuticals in Q4 2022 and held it in 3 quarters.
NewSquare Capital's Madrigal Pharmaceuticals position peaked at $1.45K in Q4 2022.
205 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.